|
|
|
|
|
|
|
|
|
|
|
|
|
Imprints On Oral Solid Dosage Forms
|
|
Case Study | By Jonas Schäfer and Lutz Drügemöller, Rottendorf Pharma GmbH
|
Selecting the right tablet imprinting technology is essential for product identification and compliance. Improve your print clarity, speed, and overall manufacturing efficiency.
|
|
|
|
|
|
|
|
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., deputy chief editor, Outsourced Pharma
|
From supplier substitutions to release testing, raw-material decisions deserve the same sponsor scrutiny as the CDMOs that manufacture them.
|
|
|
|
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., deputy chief editor, Outsourced Pharma
|
There are various outsourcing models in pharma—from CDMOs (for formulation/production) to CROs (for clinical trials) to FSPs (supplying specialized talent). Which is the right fit, and how do you choose? In this episode, editorial board member Tom Holmes talks about how to choose the right outsourcing model, balance speed-to-clinic, manage blended models, and course-correct midstream.
|
|
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
